ALNYLAM PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase Decrease In Operating Lease Liability of -$37.84 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2024-10-31
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$14.05M.
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$10.95M.
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$12.84M.
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2023-12-31 was -$11.49M.
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$46.50M.
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was -$43.17M.
- ALNYLAM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2021 was -$40.35M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$14.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$25.00M derived: sum of 2 quarters · filed 2024-10-31 | -$37.84M 10-Q · filed 2024-10-31 | -$49.33M derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-06-30 | -$10.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$23.79M 10-Q · filed 2024-08-01 | -$35.28M derived: sum of 3 quarters · filed 2024-08-01 | -$46.45M derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-03-31 | -$12.84M 10-Q · filed 2024-05-02 | -$24.33M derived: sum of 2 quarters · filed 2024-05-02 | -$35.49M derived: sum of 3 quarters · filed 2024-10-31 | -$46.52M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-12-31 | -$11.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$22.66M derived: sum of 2 quarters · filed 2024-10-31 | -$33.67M derived: sum of 3 quarters · filed 2024-10-31 | -$46.50M 10-K · filed 2024-02-15 |
| 2023-09-30 | -$11.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$22.19M derived: sum of 2 quarters · filed 2024-10-31 | -$35.01M 10-Q · filed 2024-10-31 | -$46.47M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$11.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$23.85M 10-Q · filed 2024-08-01 | -$35.30M derived: sum of 3 quarters · filed 2024-08-01 | -$45.58M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$12.83M 10-Q · filed 2024-05-02 | -$24.28M derived: sum of 2 quarters · filed 2024-05-02 | -$34.56M derived: sum of 3 quarters · filed 2024-05-02 | -$45.33M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$11.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$21.74M derived: sum of 2 quarters · filed 2024-02-15 | -$32.50M derived: sum of 3 quarters · filed 2024-02-15 | -$43.17M 10-K · filed 2024-02-15 |
| 2022-09-30 | -$10.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$21.05M derived: sum of 2 quarters · filed 2023-11-02 | -$31.72M 10-Q · filed 2023-11-02 | -$42.48M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$10.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$21.43M 10-Q · filed 2023-08-03 | -$32.20M derived: sum of 3 quarters · filed 2024-02-15 | |
| 2022-03-31 | -$10.67M 10-Q · filed 2023-05-04 | -$21.44M derived: sum of 2 quarters · filed 2024-02-15 | ||
| 2021-12-31 | -$10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$40.35M 10-K · filed 2024-02-15 | ||
| 2021-09-30 | -$29.59M 10-Q · filed 2022-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |